Alex B Blair1, Richard A Burkhart1, James F Griffin1, James A Miller2, Matthew J Weiss1, John L Cameron1, Christopher L Wolfgang1, Jin He3. 1. Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland; The Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland; The Sol Goldman Pancreatic Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland. 2. The Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland; The Sol Goldman Pancreatic Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland; Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland. 3. Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland; The Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland; The Sol Goldman Pancreatic Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland. Electronic address: jhe11@jhmi.edu.
Abstract
BACKGROUND: Sarcomatoid carcinoma of the pancreas (SCP) is a rare histologic subtype of undifferentiated pancreatic carcinoma. Historically, this has been associated with a worse overall prognosis than adenocarcinoma. However, the clinical course and surgical outcomes of SCP remain poorly characterized owing to its rarity. METHODS: A single-institution, prospectively maintained database was queried for patients who underwent pancreatic resection with a final diagnosis of SCP. We describe their histology, clinicopathologic features, and perioperative outcomes. Survival data are highlighted, and common traits of long-term survivors are examined. RESULTS: Over a 25-year period, 7009 patents underwent pancreatic resection at our institution. Eight (0.11%) were diagnosed with SCP on final histopathology. R0 resection was achieved in six patients (75%). Four patients had early recurrence leading to death (<3 months). Two (25%) experienced long-term survival (>5 years), with the longest surviving nearly 16 years despite the presence of lymph node metastasis. There were no deaths attributed to perioperative complications. Both long-term survivors had disease in the body/tail of the pancreas and received adjuvant radiotherapy. One also received adjuvant gemcitabine-based chemotherapy. CONCLUSIONS: SCP is a rarely appreciated subset of pancreatic malignancy that does not necessarily portend to a uniformly dismal prognosis. Although some have rapid recurrence and an early demise, long-term survival may be possible. Future studies are needed to better define the cohort with potential for long-term survival so that aggressive therapies may be tailored appropriately in this patient subset.
BACKGROUND:Sarcomatoid carcinoma of the pancreas (SCP) is a rare histologic subtype of undifferentiated pancreatic carcinoma. Historically, this has been associated with a worse overall prognosis than adenocarcinoma. However, the clinical course and surgical outcomes of SCP remain poorly characterized owing to its rarity. METHODS: A single-institution, prospectively maintained database was queried for patients who underwent pancreatic resection with a final diagnosis of SCP. We describe their histology, clinicopathologic features, and perioperative outcomes. Survival data are highlighted, and common traits of long-term survivors are examined. RESULTS: Over a 25-year period, 7009 patents underwent pancreatic resection at our institution. Eight (0.11%) were diagnosed with SCP on final histopathology. R0 resection was achieved in six patients (75%). Four patients had early recurrence leading to death (<3 months). Two (25%) experienced long-term survival (>5 years), with the longest surviving nearly 16 years despite the presence of lymph node metastasis. There were no deaths attributed to perioperative complications. Both long-term survivors had disease in the body/tail of the pancreas and received adjuvant radiotherapy. One also received adjuvant gemcitabine-based chemotherapy. CONCLUSIONS:SCP is a rarely appreciated subset of pancreatic malignancy that does not necessarily portend to a uniformly dismal prognosis. Although some have rapid recurrence and an early demise, long-term survival may be possible. Future studies are needed to better define the cohort with potential for long-term survival so that aggressive therapies may be tailored appropriately in this patient subset.
Authors: Susana De la Riva; Miguel A Muñoz-Navas; Maite Betés; Jose C Súbtil; Cristina Carretero; Jesus J Sola Journal: Gastrointest Endosc Date: 2006-09-01 Impact factor: 9.427
Authors: Pablo E Serrano; Sean P Cleary; Neesha Dhani; Peter T W Kim; Paul D Greig; Kenneth Leung; Carol-Anne Moulton; Steven Gallinger; Alice C Wei Journal: Ann Surg Oncol Date: 2014-10-28 Impact factor: 5.344
Authors: Oliver Strobel; Werner Hartwig; Frank Bergmann; Ulf Hinz; Thilo Hackert; Lars Grenacher; Lutz Schneider; Stefan Fritz; Matthias M Gaida; Markus W Büchler; Jens Werner Journal: Surgery Date: 2010-06-09 Impact factor: 3.982
Authors: Jill C Moore; Kristen Hilden; Joel S Bentz; Randall K Pearson; Douglas G Adler Journal: Gastrointest Endosc Date: 2009-01 Impact factor: 9.427
Authors: C J Yeo; J L Cameron; K D Lillemoe; J V Sitzmann; R H Hruban; S N Goodman; W C Dooley; J Coleman; H A Pitt Journal: Ann Surg Date: 1995-06 Impact factor: 12.969